BridgeBio Pharma Inc (NASDAQ:BBIO) saw a downside of -0.70% to close Monday at $27.08 after subtracting -$0.19 on the day. The 5-day average trading volume is 1,450,020 shares of the company’s common stock. It has gained $28.83 in the past week and touched a new high 1 time within the past 5 days. An average of 1,960,605 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,383,118.
BBIO’s 1-month performance is -3.56% or -$2.60 on its low of $26.22 reached on 09/25/23. The company’s shares have touched a 52-week low of $6.64 and high of $36.36, with the stock’s rally to the 52-week high happening on 07/18/23. YTD, BBIO has achieved 255.38% or $19.46 and has reached a new high 21 times. However, the current price is down -25.52% from the 52-week high price.
Insider Transactions
BBIO stock investors last saw insider trading activity on Sep 05.Scott Randal W. (Director) most recently sold 2,500 shares at $30.00 per share on Sep 05. This transaction cost the insider $75,000. CEO and President, Kumar Neil, sold 51,552 shares at a price of $28.59 on Aug 17. Then, on Aug 17, Secretary, Treasurer & CFO STEPHENSON BRIAN C sold 22,683 shares at a price of $28.59 per share. This transaction amounted to $648,455.
Valuation Metrics
BBIO stock has a beta of 0.99. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 775.96.
BridgeBio Pharma Inc’s quick ratio for the period ended June 29 was 3.93, with the current ratio over the same period at 3.93. In terms of profitability, the gross margin trailing 12 months is -25.30%. The firm’s gross profit as reported stood at $74.21 million against revenue of $77.65 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 93.76% to -$157.9 million, while revenue of -$140.16 million was 11.23% off the previous quarter. Analysts expected BBIO to announce -$0.83 per share in earnings in its latest quarter, but it posted -$0.98, representing a -18.10% surprise. EBITDA for the quarter stood at more than -$144.46 million. BBIO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 1.85 billion, with total debt at $1.73 billion. Shareholders hold equity totaling $162.47 million.
Let’s look briefly at BridgeBio Pharma Inc (BBIO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 25 September was 34.18% to suggest the stock is trending Neutral, with historical volatility in this time period at 32.70%.
The stock’s 5-day moving average is $27.44, reflecting a -5.12% or -$1.46 change from its current price. BBIO is currently trading -8.76% above its 20-day SMA, +93.98% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +48.63% and SMA200 by+189.63%.
Stochastic %K and %D was 15.94% and 14.46% and the average true range (ATR) pointed at 1.21. The RSI (14) points at 40.12%, while the 14-day stochastic is at 20.33% with the period’s ATR at 1.28. The stock’s 9-day MACD Oscillator is pointing at -0.98 and -1.22 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for BridgeBio Pharma Inc (NASDAQ: BBIO), Jefferies downgraded it to a Hold rating. They previously had a Buy rating on the stock. Analysts offering their rating for BBIO stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate BBIO as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 9 have offered a “buy” rating.
What is BBIO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $33.00 and a high of $60.00, with their median price target at $48.00. Looking at these predictions, the average price target given by analysts is for BridgeBio Pharma Inc (BBIO) stock is $46.40.
